Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors

Medicina Clinica

Volumn 141, Issue 3, 2013, Pages 95-99

  Marcé, Silvia ^a   Zamora, Lurdes ^a   Cabezón, Marta ^a   Xicoy, Blanca ^a   Boqué, Concha ^b   Fernández, Cristalina ^c   Grau, Javier ^a   Navarro, José Tomás ^a   Fernández De Sevilla, Alberto ^b   Ribera, Josep Maria ^a   Feliu, Evarist ^a   Millá, Fuensanta ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Hospital Duran y Reynals   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

ABL mutations; Chronic myeloid leukemia; Clonal cytogenetic evolution; Imatinib resistance; Second generation tyrosine kinase inhibitors

Indexed keywords

DASATINIB; IMATINIB; INTERFERON; NILOTINIB;

ABL GENE; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; GENE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ABL MUTATIONS; CHRONIC MYELOID LEUKEMIA; CLONAL CYTOGENETIC EVOLUTION; EVOLUCIÓN CITOGENÉTICA CLONAL; IMATINIB RESISTANCE; INHIBIDORES DE TIROSINA-CINASA DE SEGUNDA GENERACIÓN; LEUCEMIA MIELOIDE CRÓNICA; MUTACIONES DE ABL; RESISTENCIA A IMATINIB; SECOND-GENERATION TYROSINE KINASE INHIBITORS;

BENZAMIDES; BLAST CRISIS; CLONE CELLS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; DRUG SUBSTITUTION; FEMALE; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MUTATION; NEOPLASTIC STEM CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE ANALYSIS, DNA; THIAZOLES;

EID: 84880512092     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2012.10.028     Document Type: Article

References (27)

1. A. de Klein, A.G. van Kessel, G. Grosveld, C.R. Bartram, A. Hagemeijer, and D. Bootsma A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia Nature 5894 1982 765 767
2. N. Heisterkamp, J. Groffen, J.R. Stephenson, N.K. Spurr, P.N. Goodfellow, and E. Solomon Chromosomal localization of human cellular homologues of two viral oncogenes Nature 5885 1982 747 749
3. J.R. Engler, A. Frede, V.A. Saunders, A.C. Zannettino, T.P. Hughes, and D.L. White Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity Leukemia 4 2010 765 770
4. A. Quintas-Cardama, and J. Cortes Molecular biology of bcr-abl1-positive chronic myeloid leukemia Blood 8 2009 1619 1630
5. D. Milojkovic, and J. Apperley Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia Clin Cancer Res 24 2009 7519 7527
6. B.J. Druker, C.L. Sawyers, H. Kantarjian, D.J. Resta, S.F. Reese, and J.M. Ford Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 14 2001 1038 1042
7. M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, and F. Appelbaum Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 6 2006 1809 1820
8. T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, and J. Kaeda Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 1 2006 28 37
9. D. Marin, D. Milojkovic, E. Olavarria, J.S. Khorashad, H. de Lavallade, and A.G. Reid European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood 12 2008 4437 4444
10. T. O'Hare, C.A. Eide, and M.W. Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 7 2007 2242 2249
11. N.P. Shah, J.M. Nicoll, B. Nagar, M.E. Gorre, R.L. Paquette, and J. Kuriyan Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2002 117 125
12. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 5682 2004 399 401
13. E. Weisberg, P.W. Manley, W. Breitenstein, J. Bruggen, S.W. Cowan-Jacob, and A. Ray Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 2 2005 129 141
14. S.H. Swerdlow Organización Mundial de la Salud and Asociación Internacional de Investigación sobre el Cancer 4th ed. WHO classification of tumours of haematopoietic and lymphoid tissues 2008 International Agency for Research on Cancer Lyon
15. J. Gabert, E. Beillard, V.H. van der Velden, W. Bi, D. Grimwade, and N. Pallisgaard Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program Leukemia 12 2003 2318 2357
16. J.S. Khorashad, M. Anand, D. Marin, S. Saunders, T. Al-Jabary, and A. Iqbal The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib Leukemia 4 2006 658 663
17. J. Cortes, A. Hochhaus, T. Hughes, and H. Kantarjian Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia J Clin Oncol 5 2011 524 531
18. J.F. Apperley Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol 11 2007 1018 1029
19. D. Bixby, and M. Talpaz Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance Hematol Am Soc Hematol Educ Program 2009 461 476
20. M.C. Muller, J.E. Cortes, D.W. Kim, B.J. Druker, P. Erben, and R. Pasquini Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations Blood 24 2009 4944 4953
21. G. Wei, S. Rafiyath, and D. Liu First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib J Hematol Oncol 2010 47
22. F.X. Gruber, T. Ernst, Y. Kiselev, A. Hochhaus, and I. Mikkola Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment Clin Chem 3 2010 469 473
23. P. Sharma, S. Mohanty, V. Kochupillai, and L. Kumar Mutations in ABL kinase domain are associated with inferior progression-free survival Leuk Lymphoma 6 2010 1072 1078
24. A. Hochhaus, M. Baccarani, M. Deininger, J.F. Apperley, J.H. Lipton, and S.L. Goldberg Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Leukemia 6 2008 1200 1206
25. H.M. Kantarjian, F.J. Giles, K.N. Bhalla, J. Pinilla-Ibarz, R.A. Larson, and N. Gattermann Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results Blood 4 2011 1141 1145
26. S. Redaelli, R. Piazza, R. Rostagno, V. Magistroni, P. Perini, and M. Marega Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants J Clin Oncol 3 2009 469 471
27. P. Valent Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? Eur J Clin Invest 10 2010 918 931